Advancing treatments for rare diseases together

Eric Teillaud

Eric Teillaud is a doctor in Pharmacy from the « Université de Bourgogne » (France) who conducted post-doctoral studies at the School of Chemical Engineering (Perdue University, USA) in Prof. Peppas’ group in Chemical Engineering and Polymer Sciences. He has over 30 years of experience in pharmaceutical R&D and quality.

Eric has worked for Merck Global Pharmaceutical Development, where he led the worldwide development of all LCM projects (drug product specifications, formulation design, analytical development, manufacturing of clinical medicines, industrial transfer and technical writing of eCTD dossiers). Working for Théramex (Merck Serono business unit specialised in women’s health therapies), he was later in charge of the management of Pharmaceutical Development of Teva Global Women’s Health project portfolio and supported the development activities for European & RoW of their commercial products. Still within Théramex, Eric took up a position as director of the pre-clinical R&D division where he was responsible for staff management, as well as for the department covering chemical development, analytics, formulation scale-up, toxicology, technical writing and project management support. He also worked for Théramex-Teva as their Head Pharmacist (QP or “Responsible Pharmacist”).
Eric now runs his own consultancy firm that offers services in drug product development strategies and pharmaceutical quality management.

At EspeRare, Eric brings his CMC and Quality experience to support and advice on the development of EspeRare’s clinical projects.

Eric Teillaud
CMC Consultant